← boardnext 2026-10-30next 2030-05
CASIF
Cali Pharmaceuticals LLCdistress 4/10 · elevated risk$0.13-7%today-95% from 52w high
Cardiovascular 1
Lead: Antibody Mediated Rejection · target CD38
Revenue
$21M
Liquidity
$19M
Runway
0.9 yrs
Shares 1y
0%
Price & events
-86.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-7.1%
1D
-7.1%
1W
-13.3%
1M
-23.5%
3M
-86.9%
6M
-89.6%
1Y
-97.8%
2Y
-99.0%
5Y
-99.5%
All
Overview
- Market Cap
- $2.67M
- Enterprise Value
- $15.94M
- Volume
- 6.90K
- 52 Week Range
- $0.10 – $2.47
- Total Shares
- 20.56M
- Float Shares
- 9.72M
- Short %
- 0.54%
- % Held by Insiders
- 45.31%
- % Held by Institutions
- 26.50%
- RVOL
- 0.54x
- Beta
- 1.42
Pipeline stages · 2 programs
CPL-01
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CID-103
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-30 Estimated 50% readout ~2027-01-13 | Phase 3 | CPL-01 | Postoperative Pain, Bunion | — | not yet recruiting |
| 2030-05 Estimated 50% readout ~2030-06-15 | Phase 1/2 | CID-103 | Antibody Mediated Rejection | — | not yet recruiting |
| 2026-06-01 | Phase 1/2 | CID-103 | Chronic Immune Thrombocytopenia | 75 | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — CD38
- none identified
Recent news
- 2026-07-22Early-Stage CID-103 Trial Puts CASI Pharmaceuticals on Investors’ Watchlist - TipRanks
- 2026-07-20Price to earnings forward of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
- 2026-07-15CASI Pharmaceuticals (CASIF) granted over RMB 100M in Juventas arbitration - Stock Titan
- 2026-06-29CASI Pharmaceuticals Rescinds Evomela License Termination in Settlement With Acrotech - TipRanks
- 2026-06-29CASI Pharmaceuticals (OTCQB: CASIF) ends Evomela license dispute - Stock Titan
- 2026-06-28Price to sales forward of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
- 2026-06-26CASI Pharmaceuticals, Inc. Actuals & Estimates (OTC:CASIF) - TradingView
- 2026-06-23CASI Pharmaceuticals (CASIF) files Nasdaq Form 25 to delist Ordinary Shares - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.